Articles

pharma courses

  • 31 March 2020

    ADVANCES IN HOSPITAL PHARMACY SERVICES: AN OVERVIEW

    ABOUT AUTHOR
    Dr. R. S. Thakur
    Email: drramsthakur@gmail.com
    Phone: +91-9740802164

    Preamble
    Health has direct impact on socio-economic growth of the country and welfare of its people. Hospital Pharmacy of a Hospital or other Health Care Facilities makes available drugs, devices, and other materials used in the diagnosis, mitigation, prevention and treatment of injury, illness, and disease. Hospital Pharmacy procures, stores and supplies medicines for dispensing, compounding, distribution and provides Pharmaceutical Care. Talking from a patient’s perspective, hospital pharmacy services provide medicines, information and advice to inpatients and outpatients as well as to the health professionals and others giving health care to the patients. 

  • 20 March 2020
    Diabetic nephropathy : A Review

    ABOUT AUTHORS
    Navneet Kaur1, Latika Khosla2
    1Department of Biotechnology, CT Institute of Pharmaceutical Sciences, Shahpur, Jalandhar-144001, Punjab.
    2Department of Biotechnology, Kanya Maha Vidyalaya, Jalandhar-144004, Punjab

    ABSTRACT
    Diabetic nephropathy (DN) is defined as a progressive pathological condition of the kidney caused by angiopathy of glomerular capillaries. The angiopathy of these capillaries is characterized by a progressive loss of glomerular filtration surface areas and capillary volume. DN is the leading cause of end-stage renal disease, and a major contributing factor to morbidity and mortality of diabetic patients throughout the world.

  • Foreign direct investment (FDI) is continuously declining in India. It is second time since 2014, there is a steady decline reported in 2019-20. It was Rs. 9994 crores in 2014-15 and declined to Rs. 2496 crore in 2019-2020 as reported by department of pharmaceuticals.

  • 12 March 2020
    HIGH PERFORMANCE ENVIRONMENT FRIENDLY WATER-BASED HEAT SEAL COATING FOR PTP

    ABOUT AUTHOR
    Abhineet Shrivastava    1, Soumyanath Mishra2
    1 Manager, Overseas business development department Coating and Engineering material division, Mitsui Chemicals Inc
    2 Head, Packaging development, Mankind Pharmaceutical Ltd.

    Environment pollution : Case of China and what India can learn from it

    As global economy is growing, the problem of environment pollution is also increasing rapidly and now it cannot be overlooked anymore. Indeed it is imperative for countries globally to restore their ecological environment. In 2016 the World health Organization (WHO) released a report on atmospheric pollution. In this report it is said that 92% of the world’s population are exposed to atmospheric pollution of hazardous level. Data from International Energy Agency (IEA) also shows that in 2016 , 6.5 million died as a result of atmospheric pollution. One of the cause for atmospheric pollution is the use of organic solvents during industrial production. Therefore, a matter that urgently needs to be addressed is the reduction of use of organic solvent in order to reduce VOC emission.

  • 2 February 2020
    CHALLENGES FOR FDA WITH FOREIGN INSPECTIONS

    As per analysis of United States Government Accountability Office (GAO), preliminary analysis of Food and Drug Administration (FDA) data shows that from fiscal year 2012 through 2016, the number of foreign drug manufacturing establishment inspections increased. From fiscal year 2016 through 2018, both foreign and domestic inspections decreased by about 10 percent and 13 percent, respectively.

  • 25 January 2020
    Highest Pharmaceutical mergers and acquisitions of 2019

    Mergers and acquisitions (M&As) are perpetual part of big pharmaceutical industries and we have witnessed many such mergers and acquisitions. The financial crisis and resulting uncertainty in the global economies has made it difficult for companies to predict future performance of their own or their targets or to forecast synergies and other transaction benefits with the same level of confidence seen in the past. As a result, acquirors and targets have developed transaction structures that are aimed at bridging gaps in their respective assessments of valuation and risk.

    This article is focusing on top Pharmaceutical M&As of the year 2019.

  • 11 January 2020
    Metabolic Syndrome : A Review

    ABOUT AUTHOR
    Navneet Kaur1, Narinder Singh2, Daisy Sharma2.
    1Department of Biotechnology, CT Institute of Pharmaceutical Sciences, Shahpur, Jalandhar-144001, Punjab.
    2Department of Pharmaceutics, CT Institute of Pharmaceutical Sciences, Shahpur, Jalandhar-144001, Punjab

    ABSTRACT
    Metabolic syndrome is defined by a group of interconnected physiological and a few biochemical or clinical disorder which directly affect the high risk rate of diseases such as cardiovascular disease (hypertension) also causing type 2 diabetes mellitus and mortality. The metabolic syndrome is higher prevalence in Western counterparts other than the urban population of some emerging countries. In the review Definition of syndrome, pathophysiology, and some criteria would be proposed for the clinical diagnosis and underlying management approaches for metabolic syndrome.

  • Antibiotic resistance (AMR) is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. Antimicrobial Resistance is an increasingly serious threat to public health. The spread of multi-drug resistant bacteria and the lack of new antibiotics to treat infections caused by these organisms pose a rapidly increasing threat to human health which urgently needs to be tackled.

  • 26 December 2019
    ORPHAN DRUGS IN INDIA AND CHALLENGES

    Orphan drugs are medicinal products intended for diagnosis, prevention or treatment of life-threatening or very serious diseases or disorders that are rare. In USA, the Orphan Drug Act was passed in 1983 to give drug companies incentives to develop treatments for rare diseases. India does not have laws on orphan drugs though CDSCO defined orphan drugs as those intended to treat a condition which affects fewer than 200,000 people.

  • 21 December 2019
    Decreasing Therapy Cost, For people by People: Collobrative approach

    Development of new biopharmaceutical for different patient's need is now in some limited hand due to high R&D (Research and Development) cost and making therapy are not affordable for large segment of people in developing country.

Subscribe to Articles